HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

UR 12633

structure given in first source

Also Known As:

1-(1-oxo-3,3-diphenylpropyl)-alpha-3-pyridinyl-4-piperidineacetonitrile; UR-12633

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - UR 12633: 1

Related Diseases

1.	Shock 07/01/1996 - "7. In spite of the multifactorial nature of endotoxic shock, in which many mediators may be involved, the new potent PAF antagonist, UR-12633, proved effective in protecting against changes in most shock markers. " 07/01/1996 - "1. The effects of the selective and potent novel platelet-activating factor (PAF) antagonist, UR-12633 (1-(3,3-diphenylpropionyl)-4-(3-pyridylcyanomethyl)piperidin e) on several markers of endotoxic shock syndrome were evaluated in rats and mice. " 07/01/1996 - "Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock."
2.	Hypotension (Low Blood Pressure) 07/01/1996 - "UR-12633 (1 mg kg-1), administered 10 min before LPS, almost fully inhibited sustained hypotension. " 07/01/1996 - "The immediate hypotension (within 1 min) caused by LPS was not prevented by either UR-12633 or WEB-2086. "
3.	Disseminated Intravascular Coagulation 07/01/1996 - "3. Pretreatment with 10 mg kg-1, i.v. of either UR-12633 or WEB-2086 inhibited the increase in disseminated intravascular coagulation markers, such as activated partial thromboplastin time (55 and 74% inhibition, respectively), and prothrombin time (22 and 72% inhibition) and prevented the decrease in plasma fibrinogen content (100 and 29% inhibition). "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Fibrinogen (Factor I)
3.	WEB 2086 (apafant)